Partner Article
Quantum Pharma CEO resigns ‘for family reasons’
Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, has tendered his resignation as a Director of the firm for family reasons.
Mr Scaife has agreed to remain at the business’ helm until a new appointment is confirmed and to facilitate a smooth handover.
The Durham-based pharmaceutical developer, manufacturer and supplier’s announcement this morning follows a key board level change already this year.
The company promoted Chris Rigg to the role of Chief Financial Officer in March , following Martin Such’s resignation. A formal search process to secure Andrew’s replacement will reportedly begin ‘as soon as possible’.
Quantum’s Chairman, John Clarke, said: “Andrew has made a significant contribution to the Group during the past seven years and has been instrumental to the Group’s growth and strategic direction, and to its admission to AIM in 2014.
“On behalf of the Board of directors of the Company, I would like to thank Andrew for his contribution and wish him the best for his future career.”
The business will hold its Annual General Meeting in Newcastle later today.
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
The true value of HR in an AI-driven working world
What new business rates guidance means for pubs
Business success starts with people investment
It's time to confront the digital poverty crisis
Why a business exit is no longer all or nothing
Culture is the foundation for sustainable growth
Business must help young people take root in work
Purposeful procurement for long-term growth
Time to rethink outdated views on apprenticeships
The scale-ups rocketing through our fast world
Care about the experience, not just the outcome
The rise of an alternative investor model